The cutaneous toxicity of MEK inhibitors may limit treatment adherence. The authors present a retrospective study of 41 paediatric patients with NF-1 undergoing therapy with selumetinib and propose a treatment algorithm.
No takes yet. Share an insight, caveat, or question.
Palmeiro et al. (2023) studied this question.